Senate Committee Investigates Ozempic and Wegovy Costs - NYT
Tweet
Share
E-mail
Get Alerts NVO Hot Sheet
Join SI Premium – FREE
(Updated - April 24, 2024 12:04 PM EDT)
Senate Committee Investigates Ozempic and Wegovy Costs - NYT
- Senator Bernie Sanders is pressing Novo Nordisk (NYSE: NVO) for details on its pricing of the popular diabetes and weight loss medications.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- NVIDIA (NVDA) in talks to invest in data-center company Cloverleaf Infrastructure - WSJ
- FTC files amicus brief challenging Amgen's Enbrel patent acquisition
Create E-mail Alert Related Categories
Politics, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
